Mentions of digitalization within the filings of companies in the medical devices industry were 260% higher between October 2020 and September 2021 than in 2016, according to the latest analysis of data from GlobalData.
When companies in the medical devices industry publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Digitalization is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.
To assess whether digitalization is featuring more in the summaries and strategies of companies in the medical devices industry, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned digitalization at least once in filings during the past twelve months - this was 79% compared to 47% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to digitalization.
Of the 50 biggest employers in the medical devices industry, Align Technology Inc was the company which referred to digitalization the most between October 2020 and September 2021. GlobalData identified 215 digitalization-related sentences in the United States-based company's filings - 3.2% of all sentences. Fleury SA mentioned digitalization the second most - the issue was also referred to in 3.2% of sentences in the company's filings. Other top employers with high digitalization mentions included Fresenius SE & Co KGaA, Hoya Corp and Dragerwerk AG & Co KGaA.
Across all companies in the medical devices industry the filing published in the third quarter of 2021 which exhibited the greatest focus on digitalization came from Tandem Diabetes Care Inc. Of the document's 1,007 sentences, nine (0.9%) referred to digitalization.
This analysis provides an approximate indication of which companies are focusing on digitalization and how important the issue is considered within the medical devices industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning digitalization more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into digitalization have been successes or failures.
In the last quarter, companies in the medical devices industry based in Western Europe were most likely to mention digitalization with 0.49% of sentences in company filings referring to the issue. In contrast, companies with their headquarters in the United States mentioned digitalization in just 0.2% of sentences.